Fisher Strengthens its Reagent Portfolio Through Acquisition of BioImage
News Apr 28, 2006
BioImage, which is based in Copenhagen, Denmark, complements Fisher Biosciences' existing Cellomics business.
The Cellomics platform includes automated imaging instrumentation, BioApplication image analysis software, High Content Informatics software and HitKit® HCS Reagent kits.
The entire Cellomics product portfolio is fully integrated to improve the quality and productivity of high content cell-based assays.
BioImage is a leader in the field of High Content Pathway analysis, providing the life-science market with products, services and licenses that are based on its Redistribution® technology.
Redistribution is a patented technology that monitors protein translocation within a cell and is the basis for many of today's high content assays.
"The addition of BioImage further enhances our portfolio of high content cell-based assays and reagents," said Ron Lowy, president and chief executive officer of Fisher Biosciences.
"Adding BioImage's Redistribution IP, assays, cell-lines and services to our already strong offering of high content screening instrumentation, software, siRNA and assay reagent kits, provides a more complete range of options to customers and strengthens Fisher's leadership position in high content screening."
Fisher will continue operations in Copenhagen.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.